Plus Therapeutics, Inc. (NASDAQ:PSTV) Short Interest Down 32.2% in February

Plus Therapeutics, Inc. (NASDAQ:PSTV) was the target of a large decline in short interest in the month of February. As of February 15th, there was short interest totalling 59,900 shares, a decline of 32.2% from the January 31st total of 88,400 shares. Approximately 1.0% of the shares of the company are short sold. Based on an average daily trading volume, of 55,200 shares, the days-to-cover ratio is currently 1.1 days.

Analyst Ratings Changes

PSTV has been the subject of several recent analyst reports. Ascendiant Capital Markets cut their price target on Plus Therapeutics from $20.00 to $19.00 and set a “buy” rating for the company in a research note on Monday, December 9th. HC Wainwright restated a “buy” rating and issued a $8.00 price target on shares of Plus Therapeutics in a research note on Tuesday, November 26th.

Plus Therapeutics Stock Performance

Shares of Plus Therapeutics stock traded down $0.36 on Tuesday, hitting $0.30. The company’s stock had a trading volume of 4,645,982 shares, compared to its average volume of 190,859. Plus Therapeutics has a 1 year low of $0.24 and a 1 year high of $2.67. The firm has a fifty day moving average price of $1.15 and a 200-day moving average price of $1.29. The company has a market capitalization of $1.78 million, a price-to-earnings ratio of -0.12 and a beta of 0.70.

Plus Therapeutics Company Profile

Plus Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.